6.27
+0.22(+3.64%)
Currency In USD
| Previous Close | 6.05 |
| Open | 6.29 |
| Day High | 6.93 |
| Day Low | 6.23 |
| 52-Week High | 11.41 |
| 52-Week Low | 1.73 |
| Volume | 1.49M |
| Average Volume | 670,743 |
| Market Cap | 194.38M |
| PE | -3.52 |
| EPS | -1.78 |
| Moving Average 50 Days | 7.41 |
| Moving Average 200 Days | 6.27 |
| Change | 0.22 |
If you invested $1000 in Sagimet Biosciences Inc. (SGMT) since IPO date, it would be worth $393.1 as of December 17, 2025 at a share price of $6.27. Whereas If you bought $1000 worth of Sagimet Biosciences Inc. (SGMT) shares 1 year ago, it would be worth $1,055.56 as of December 17, 2025 at a share price of $6.27.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
GlobeNewswire Inc.
9 hours ago
License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applicationsCollaboration supports Sagimet’s fixed-dose combination (FD
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
GlobeNewswire Inc.
Dec 10, 2025 12:03 PM GMT
SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Asc
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Dec 09, 2025 9:05 PM GMT
SAN MATEO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in